The court affirmed a lower court ruling that Eli Lilly's schizophrenia drug patent is valid, rejecting efforts by the Ivax unit of Teva Pharmaceutical Industries and Dr. Reddy's Laboratories to overturn Lilly's 2011 patent expiration. The judges also said "Lilly did not fail to disclose information" to the patent office as the two rival drugmakers had argued.

Full Story:

Related Summaries